Oculis Holding AG (OCS)
About Oculis Holding AG
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $677.0M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $677.0M
- Shares outstanding
- 60.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 3, 2023
Oculis Holding AG (OCS) Stock Price
- Trading 66% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Oculis Holding AG.
Write a review
News about Oculis Holding AG
News & sentiment via Polygon.io
Oculis Holding AG: frequently asked questions
Is Oculis Holding AG an American company?
Oculis Holding AG is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Oculis Holding AG publicly traded?
Yes — Oculis Holding AG is a publicly traded company. Its stock trades under the ticker symbol OCS on the NASDAQ.
What does Oculis Holding AG do?
Oculis Holding AG is an American Pharmaceuticals company in the Health & Beauty sector.
